You are accessing a medical content website
Are you a health professional?

Log in EspañolEspañolEnglish English @RevEspCardiol Facebook RSS
Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2017;70:247-53 - Vol. 70 Num.04 DOI: 10.1016/j.rec.2016.09.024

Long-term Follow-up of Patients With Severe Aortic Stenosis Treated With a Self-expanding Prosthesis

Pablo Avanzas a, Isaac Pascual a, Antonio J. Muñoz-García b, José Segura c, Juan H. Alonso-Briales b, Javier Suárez de Lezo c, Manuel Pan c, Manuel F. Jiménez-Navarro b, José López-Aguilera c, José M. Hernández-García b,, César Morís a

a Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
b Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
c Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain

Refers to


TAVI. Aortic stenosis. Prognosis. Treatment.


Introduction and objectives

Transcatheter aortic valve implantation (TAVI) is a safe and effective alternative to surgical treatment in patients with severe aortic stenosis (AS) and those who are inoperable or at high surgical risk. The primary objective of this study was to evaluate the long-term survival of consecutive patients with severe AS treated with TAVI.


Observational, multicenter, prospective, follow-up study of consecutive patients with severe symptomatic AS treated by TAVI in 3 high-volume hospitals in Spain.


We recruited 108 patients, treated with a self-expanding CoreValve prosthesis. The mean age at implantation was 78.6 ± 6.7 years, 49 (45.4%) were male and the mean logistic EuroSCORE was 16% ± 13.9%. The median follow-up was 6.1 years (2232 days). Survival rates at the end of years 1, 2, 3, 4, 5, and 6 were 84.3% (92.6% after hospitalization), 77.8%, 72.2%, 66.7%, 58.3%, and 52.8%. During follow-up, 71 patients (65.7%) died, 18 (25.3%) due to cardiac causes. Most (82.5%) survivors were in New York Heart Association class I or II. Six patients (5.5%) developed prosthetic valve dysfunction.


Long-term survival in AS patients after TAVI is acceptable. The main causes of death are cardiovascular in the first year and noncardiac causes in subsequent years. Valve function is maintained over time.

1885-5857/© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved